These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The treatment of postmenopausal syndrome by monthly oral doses of quinestrol.
    Author: Jaschevatzky OE, Anderman S, Shalit A, Kampf D, Grünstein S.
    Journal: Acta Obstet Gynecol Scand; 1979; 58(2):175-8. PubMed ID: 452871.
    Abstract:
    Seventy patients between the ages of 37 and 59 suffering from the menopausal syndrome were included in a clinical trial and treated for a period of 6 to 18 months. Out of the seventy, 43 were suffering from spontaneous and 27 from surgical menopause. Forty of them were given 1 mg of quinestrol and 30 received placebo. The drug was administered orally in a one-tablet dose once a month. An improvement took place in 35 (87.5%) of the women receiving quinestrol but in only 15 (50%) of those receiving placebo. Among the patients with spontaneous menopause an improvement was seen in 22 out of 25 (88%) receiving quinestrol, compared with 9 out of 18 (50%) receiving placebo. Tolerance of the drug was good and most of the laboratory tests as well as blood pressure and body weight showed statistically non-significant changes. This kind of treatment is expecially suitable when daily intake is undesirable. Use of small daily doses of quinestrol, a synthetic estrogen consisting of 3 cyclopenthyl-ether of ethinyl estradiol, has been reported to result in remission of postmenopausal symptoms in many patients. This study used quinestrol in 1 mg monthly oral doses in a group of women (N=70) suffering from the menopausal syndrome (43 from spontaneous and 27 from surgical menopause). 40 women received quinestrol 1 mg and 30 were given placebo. Of the 40 who were given quinestrol, 25 had spontaneous menopause and 15 were surgically induced. In the placebo group, 18 had spontaneous menopause and 12 were surgically induced. Treatment lasted from 6-18 months; none of the patients knew whether they had quinestrol or placebo. Blood samples were taken in 10 patients before treatment and 6 months later. As a whole, improvement was observed in 87.5% of the quinestrol-treated group, in contrast to 50% of the placebo-treated group. For women with spontaneous menopause, an improvement was observed in 88% of the quinestrol group and 50% of the placebo group. With respect to the effectiveness of quinestrol, no significant difference in the relief of symptoms was observed between the 2 groups (spontaneous and surgical menopause). Observed side effects were skin rash in 2 patients, thrombophlebitis in 1 patient, vaginal bleeding in 3 patients and nausea in 4 patients. It was concluded that quinestrol therapy is especially suitable in surgical menopause where substitutive therapy is indicated, as well as in cases where daily intake is not favored.
    [Abstract] [Full Text] [Related] [New Search]